X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used to fund the clinical trial for WCK 5222, a combination of cefepime and the novel β-lactam enhancer (BLE) zidebactam, currently being studied in a global Phase 3 trial in complicated urinary tract infection.
Lead Product(s): Cefepime,Zidebactam
Therapeutic Area: Infections and Infectious Diseases Product Name: WCK 5222
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: ICICI Prudential
Deal Size: $57.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 28, 2024
Details:
Glenmark has acquired the approved ANDAs for Famotidine Tablets USP, 10 mg and 20 mg, Cetirizine Hydrochloride Tablets USP, 5 mg and 10 mg, Lansoprazole DelayedRelease Capsules USP, 15 mg and Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% from Wockhardt Limited.
Lead Product(s): Famotidine
Therapeutic Area: Gastroenterology Product Name: Famotidine- Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Glenmark Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 28, 2022
Details:
Under the terms of the definitive agreement, Jemincare will be responsible for exclusive development and commercialization of the Nafithromycin in the select markets.
Lead Product(s): Nafithromycin
Therapeutic Area: Infections and Infectious Diseases Product Name: WCK 4873
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jiangxi Jemincare Group Company
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 26, 2021
Details:
Wockhardt has reserved manufacturing capacity to allow for the supply of multiple vaccines to the UK Government in its fight against COVID19, including AZD1222, the vaccine co-invented by the University of Oxford and its spinout company, Vaccitech and licensed by AstraZeneca.
Lead Product(s): ChAdOx1 nCoV-19
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: UK Government
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 03, 2020
Details:
Wockhardt Ltd will supply millions of doses of multiple COVID-19 vaccines, including that being developed by AstraZeneca and Oxford University, under a deal with the UK government.
Lead Product(s): ChAdOx1 nCoV-19
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: U.S Government
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 03, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
